Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Vesugen
A Khavinson-series short peptide studied in cell cultures and by computer docking; no vascular benefit in people has been shown.
Cardiogen
A Khavinson-series tetrapeptide tested on rat heart-tissue explants in a dish; not the CardioGen-82 heart-imaging agent, and not tested on living hearts.
How far human research has progressed
Vesugen
Preclinical (cell culture and molecular docking)Cardiogen
Preclinical (organotypic tissue culture)Claim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Vesugen
Not separately assessed; see the full profile.Cardiogen
Not separately assessed; see the full profile.Human research context
Vesugen
Preclinical (cell culture and molecular docking)Cardiogen
Preclinical (organotypic tissue culture)Human efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Vesugen
Cardiogen
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Vesugen
Cardiogen
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Vesugen
Cardiogen
Regulatory status (legal position, not proof it works)
Vesugen
Check jurisdiction-specific details in the profile.
Not an approved medicine in any major jurisdiction. Sale as a 'research chemical' is a legal and supply-chain statement, not evidence of benefit or harm.
Cardiogen
Check jurisdiction-specific details in the profile.
Not an approved medicine in any major jurisdiction. Sale as a 'research chemical' is a legal and supply-chain statement, not evidence of benefit or harm. Not to be confused with CardioGen-82 (rubidium-82 generator), an approved PET heart-imaging product that is unrelated to this peptide.
Common claims
Vesugen
- · Vascular protection
- · Anti-ageing of blood vessels
Cardiogen
- · Heart protection
- · Cardiac anti-ageing
How settled our evidence rating is
Vesugen
Cardiogen
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Vesugen
Not established. The only cited finding is increased cell-proliferation marker expression, which is a reason for caution rather than a finding of risk.Cardiogen
Not established. Increased proliferation and reduced p53 in tissue culture are reasons for caution, not findings of risk.What this adds up to, in plain English
Vesugen
This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.Cardiogen
This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.A comparison is not a recommendation